#159 ICON8B: GCIG phase III randomised trial comparing weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy+ bevacizumab in first-line high-risk stage III-IV epithelial ovarian cancer treatment: primary progression-free survival analysisAndrew R. Clamp, Jonathan A. Ledermann, Sharadah Essapen et al.|International Journal of Gynecological Cancer|2023Cited by 4
ICON8B: GCIG phase III randomised trial comparing first-line weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy + bevacizumab in high-risk stage III-IV epithelial ovarian cancer: final overall survival (OS) analysisA. Clamp, Jonathan A. Ledermann, Domenico Radice et al.|International Journal of Gynecological Cancer|2026Cited by 1